loading
Precedente Chiudi:
$62.24
Aprire:
$62.06
Volume 24 ore:
862.72K
Relative Volume:
0.60
Capitalizzazione di mercato:
$6.52B
Reddito:
$628.56M
Utile/perdita netta:
$141.82M
Rapporto P/E:
49.89
EPS:
1.26
Flusso di cassa netto:
$142.60M
1 W Prestazione:
-7.01%
1M Prestazione:
+6.90%
6M Prestazione:
+27.68%
1 anno Prestazione:
+173.22%
Intervallo 1D:
Value
$61.75
$64.26
Intervallo di 1 settimana:
Value
$61.75
$70.37
Portata 52W:
Value
$20.84
$117.33

Corcept Therapeutics Inc Stock (CORT) Company Profile

Name
Nome
Corcept Therapeutics Inc
Name
Telefono
650.688.8803
Name
Indirizzo
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Name
Dipendente
352
Name
Cinguettio
Name
Prossima data di guadagno
2025-02-17
Name
Ultimi documenti SEC
Name
CORT's Discussions on Twitter

Confronta CORT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CORT
Corcept Therapeutics Inc
62.86 6.52B 628.56M 141.82M 142.60M 1.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.92 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.59 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
597.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
231.91 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.69 26.16B 3.81B -644.79M -669.77M -6.24

Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-11-06 Aggiornamento Truist Hold → Buy
2023-04-11 Iniziato SVB Securities Market Perform
2023-04-04 Iniziato Piper Sandler Overweight
2023-02-15 Downgrade Jefferies Buy → Hold
2022-08-01 Downgrade Truist Buy → Hold
2022-07-27 Aggiornamento Jefferies Hold → Buy
2022-06-27 Ripresa Canaccord Genuity Buy
2022-02-02 Iniziato Canaccord Genuity Buy
2022-01-28 Iniziato Truist Buy
2020-08-05 Downgrade Jefferies Buy → Hold
2019-09-24 Iniziato Jefferies Buy
2019-09-06 Iniziato H.C. Wainwright Buy
2019-02-04 Downgrade B. Riley FBR Buy → Neutral
2018-08-10 Reiterato Stifel Hold
2018-05-31 Downgrade Stifel Buy → Hold
2018-03-09 Iniziato B. Riley FBR, Inc. Buy
2017-08-31 Iniziato Stifel Buy
2017-02-02 Iniziato Ladenburg Thalmann Buy
2015-04-21 Iniziato FBR Capital Outperform
2014-01-13 Downgrade Stifel Buy → Hold
2013-08-09 Downgrade Janney Buy → Neutral
2013-08-09 Downgrade Ladenburg Thalmann Buy → Neutral
2012-02-21 Reiterato JMP Securities Mkt Outperform
2010-01-06 Aggiornamento Ladenburg Thalmann Neutral → Buy
2008-07-17 Iniziato Rodman & Renshaw Mkt Outperform
2007-06-21 Aggiornamento Punk, Ziegel & Co Mkt Perform → Accumulate
Mostra tutto

Corcept Therapeutics Inc Borsa (CORT) Ultime notizie

pulisher
08:18 AM

Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes | CORT Stock News - GuruFocus

08:18 AM
pulisher
08:17 AM

Diabetes Care Publishes Results From Prevalence Phase Of Corcept'S CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes - marketscreener.com

08:17 AM
pulisher
08:00 AM

Landmark 1,000-Patient Diabetes Study Reveals Surprising Link to Cushing's Syndrome in Treatment-Resistant Cases - Stock Titan

08:00 AM
pulisher
Apr 16, 2025

SoundHound AI, Domo, Plug Power, Corcept, and 8x8 Shares Are Falling, What You Need To Know - Barchart.com

Apr 16, 2025
pulisher
Apr 16, 2025

$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today - Benzinga

Apr 16, 2025
pulisher
Apr 15, 2025

It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder - Seeking Alpha

Apr 15, 2025
pulisher
Apr 14, 2025

Corcept therapeutics director Daniel Swisher sells stock for $154,484 By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 14, 2025

Corcept therapeutics director Daniel Swisher sells stock for $154,484 - Investing.com

Apr 14, 2025
pulisher
Apr 09, 2025

Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter - Yahoo

Apr 09, 2025
pulisher
Apr 07, 2025

Corcept Initiates Trial Of Relacorilant Plus NAB-Paclitaxel And Bevacizumab - MarketScreener

Apr 07, 2025
pulisher
Apr 07, 2025

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer - Business Wire

Apr 07, 2025
pulisher
Apr 07, 2025

Breakthrough Ovarian Cancer Trial Combines Three Powerful Treatments in Phase 2 Study - Stock Titan

Apr 07, 2025
pulisher
Apr 06, 2025

How Some Mid Cap Stocks Outshone The S&P 400's Dramatic Drop Last Week (Mar 31-Apr 4) - Benzinga

Apr 06, 2025
pulisher
Apr 05, 2025

Corcept Therapeutics (NASDAQ:CORT) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

Corcept Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CORT - Benzinga

Apr 04, 2025
pulisher
Apr 04, 2025

Commonwealth Equity Services LLC Has $700,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

What is HC Wainwright’s Estimate for CORT FY2026 Earnings? - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

Corcept therapeutics officer sells $20.2 million in stock By Investing.com - Investing.com Australia

Apr 03, 2025
pulisher
Apr 03, 2025

Piper Sandler lifts Corcept stock target to $131 post-study By Investing.com - Investing.com UK

Apr 03, 2025
pulisher
Apr 03, 2025

Corcept Therapeutics’ chief development officer sells $77,639 in stock By Investing.com - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Corcept therapeutics CEO Joseph Belanoff sells $3.37 million in shares By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 02, 2025

Corcept therapeutics CEO Joseph Belanoff sells $3.37 million in shares - Investing.com Australia

Apr 02, 2025
pulisher
Apr 02, 2025

Corcept therapeutics president sells shares worth $10.1 million By Investing.com - Investing.com Canada

Apr 02, 2025
pulisher
Apr 02, 2025

Corcept Therapeutics’ chief development officer sells $77,639 in stock - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Corcept therapeutics president sells shares worth $10.1 million - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Corcept therapeutics officer sells $20.2 million in stock - Investing.com

Apr 02, 2025
pulisher
Apr 02, 2025

Corcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success - markets.businessinsider.com

Apr 02, 2025
pulisher
Apr 02, 2025

Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect? - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Corient Private Wealth LLC Purchases New Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Corcept Therapeutics (NASDAQ:CORT) Given New $142.00 Price Target at Canaccord Genuity Group - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Corcept's ovarian cancer drug meets main goal in late-stage study, shares jump - MSN

Apr 02, 2025
pulisher
Apr 01, 2025

Corcept Therapeutics stock target raised to $150 by H.C. Wainwright - Investing.com Canada

Apr 01, 2025
pulisher
Apr 01, 2025

Corcept Therapeutics (CORT) Stock Surges Following Positive Tria - GuruFocus

Apr 01, 2025
pulisher
Apr 01, 2025

Corcept Therapeutics (CORT) Surges 109% Following Positive Trial Results - GuruFocus

Apr 01, 2025
pulisher
Apr 01, 2025

U.S. Markets Ended Tuesday Mixed As monday.com Led, Corcept Therapeutics Lagged - Barron's

Apr 01, 2025
pulisher
Apr 01, 2025

Yum Brands (YUM) Seeks New CEO as Corcept (CORT) and Hut 8 (HUT) Shares Climb - GuruFocus

Apr 01, 2025
pulisher
Apr 01, 2025

Corcept Therapeutics Unusual Options Activity For April 01 - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Daily Digest: State Farm's newest rate hike request; Stock soars on cancer results - The Business Journals

Apr 01, 2025
pulisher
Apr 01, 2025

CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Corcept's relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint - Pharmafile

Apr 01, 2025
pulisher
Apr 01, 2025

Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar? - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Truist Securities lifts Corcept Therapeutics target to $150 - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Here's Why Momentum in Corcept (CORT) Should Keep going - Yahoo Finance

Apr 01, 2025
pulisher
Apr 01, 2025

Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company - Seeking Alpha

Apr 01, 2025
pulisher
Apr 01, 2025

Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday? - Yahoo

Apr 01, 2025
pulisher
Apr 01, 2025

Corcept Therapeutics Reaches Analyst Target Price - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Corcept Therapeutics Shares Surge 109% to $114.22 on Phase 3 Trial Breakthrough - TradingPedia

Apr 01, 2025
pulisher
Apr 01, 2025

Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement - Yahoo Finance

Apr 01, 2025
pulisher
Apr 01, 2025

HC Wainwright Issues Positive Forecast for Corcept Therapeutics (NASDAQ:CORT) Stock Price - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

AIG, Corcept Therapeutics, Dow - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Truist Financial Issues Positive Forecast for Corcept Therapeutics (NASDAQ:CORT) Stock Price - Defense World

Apr 01, 2025

Corcept Therapeutics Inc Azioni (CORT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$19.85
price down icon 0.77%
$71.22
price down icon 2.53%
$32.51
price up icon 0.11%
$24.83
price down icon 0.47%
$97.38
price down icon 1.48%
biotechnology ONC
$231.14
price up icon 0.63%
Capitalizzazione:     |  Volume (24 ore):